

Gynecologic Cancer: New and Follow-Up Patient Appointments in Botswana During the COVID-19 Pandemic

During the COVID-19 pandemic, there have been limited global data on cancer diagnoses and appointments. In the Netherlands, there was a 25% decrease in all non-skin cancer diagnoses and a 60% decrease in skin cancer diagnoses during the COVID-19 outbreak compared with the period before.¹ In Latin America, a survey of 453 pediatric oncohematologists demonstrated that 89% delayed their follow-up consultations,² and in Italy, a survey of 446 patients demonstrated that 44% had follow-up visits canceled.³

A commentary in the American Cancer Society emphasizes the need to expand and leverage telemedicine for oncology visits,⁴ and examples such as Kaiser Permanente in Northern California demonstrate a model for rapidly scaling telemedicine platforms during the pandemic.⁵ However, telemedicine in oncology remains very limited globally.

Oncology care during the pandemic was especially challenging in sub-Saharan Africa during COVID-19 as lockdowns resulted in several cancer centers rescheduling new patient appointments and suspending follow-ups.⁶ However, there have been no quantitative data on the impact of COVID-19 on oncology appointments in sub-Saharan Africa.

We monitored treatment initiation and follow-up of patients with gynecologic cancers who presented to the multidisciplinary team (MDT) clinic at Princess Marina Hospital (PMH) in Gaborone, Botswana, during the COVID-19 pandemic. Botswana, a country in southern Africa with a population of 2.3 million, declared a state of emergency lockdown enforcing extreme social distancing on April 3, 2020. The complete lockdown was lifted on May 21. The clinic at PMH is the primary gynecologic oncology center in Botswana. During lockdown, the clinic continued new patient appointments, but canceled follow-up appointments; follow-up appointments restarted on June 3, 2020.

The MDT clinic uses an outpatient smart phone application called OP Care, which was developed specifically for the clinic and adopted in January 2018. OP Care is able to store oncology records, electronically schedule appointments, and send automatic appointment reminders to patients.⁷ To our knowledge, OP Care is the only such telemedicine system used for oncology care in sub-Saharan Africa during the COVID-19 lockdown. Using the OP Care platform, we assessed the number of attended new patient appointments and missed follow-up appointments by week before and during the lockdown.

There was a statistically insignificant ($P = .06$) decrease in the number of patients who attended new

diagnosis appointments during the lockdown compared with no lockdown (median attended weekly new appointments: 3.5 v 6). During the weeks after the lockdown period, there was a median of 7.5 attended new appointments per week. Care coordination provided by the MDT clinic and use of OP Care to communicate with patients enabled continuation of new patient visits during the lockdown and a return of new patient visits back to baseline after the lockdown.

During the complete lockdown, all follow-up appointments were canceled by the MDT clinic. Thus, the number of unattended follow-up appointments significantly increased during the COVID-19 lockdown period compared with no lockdown (median unattended weekly follow-up appointments: 20.5 v 4, $P < .0001$). Once the complete lockdown was lifted, unattended follow-up appointments returned to baseline with a weekly median of six unattended follow-up appointments. Reasons for unattended appointments included work obligations, family duties, transportation fees, and forgetting appointment dates.⁸

During the lockdown, more than 150 follow-up appointments were canceled. OP Care provided a platform for bulk patient communication, tracking of missed appointments, and rescheduling when appointments could resume. A recent meta-analysis of 18 trials that analyzed text messaging reminders and healthcare outcomes in Africa demonstrated that text messaging reminders improved overall appointment attendance (odds ratio[OR]: 2.03, 95% CI, 1.40 to 2.95).⁹ Specifically for gynecologic cancer, a randomized controlled trial in Kenya on the effect of text messaging on cervical cancer screening attendance demonstrated patients were 8 times more likely to attend screening after a text message reminder (OR: 8.0, 95% CI, 4.7 to 13.7).¹⁰ Before COVID-19, the MDT clinic experienced a 33% increase in patients arriving to appointments ($P = .02$) when comparing the years before and after the implementation of OP Care.⁷

This is the first data demonstrating the impact of COVID-19 on oncology appointments and use of text message-based communication system in Sub-Saharan Africa during the pandemic. We showed proof of concept of the efficiency of OP Care in contracting patients to respond to the dynamic and evolving COVID-19 lockdown and appointment scheduling. Such a platform is a useful tool not just for improving overall appointment attendance, but also as a bulk patient communication tool during COVID-19 pandemic and during future unforeseen situations requiring oncology appointment cancellations in low-and-middle-income settings.

In summary, this is the descriptive data on oncology appointments during COVID-19 lockdown in sub-Saharan Africa. Mobile applications can provide a

platform for tracking missed and attended appointments. There was a significant increase in missed follow-up appointments during the COVID-19 lockdown in Botswana.

Sonya Davey, MD, MPhil

Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Lisa Bazzett-Matabele, MD

Department of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana

Barati Monare, RN, MPH

Botswana-UPenn Partnership, Gaborone, Botswana

Alexander Seiphthleng, RN, BPH and Gaobakwe Ramontshonyana, RN

Princess Marina Hospital, Gaborone, Botswana

Peter Vuylsteke, MD

Department of Internal Medicine, University of Botswana, Gaborone, Botswana

Sebathu Chiyapo, MD

Gaborone Private Hospital, Gaborone, Botswana

Rebecca Luckett, MD, MPH

Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA

Doreen Ramogola-Masire, MD

Department of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana

Surbhi Grover, MD, MPH

Botswana-UPenn Partnership, Gaborone, Botswana
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA

CORRESPONDING AUTHOR

Surbhi Grover, MD, MPH, Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19102; e-mail: Surbhi.Grover@pennmedicine.upenn.edu.

AUTHOR CONTRIBUTIONS

Conception and design: Sonya Davey, Barati Monare, Gaobakwe Ramontshonyana, Sebathu Chiyapo, Doreen Ramogola-Masire, Surbhi Grover

Administrative support: Barati Monare, Surbhi Grover

Provision of study materials or patients: Barati Monare, Alexander Seiphthleng, Gaobakwe Ramontshonyana, Peter Vuylsteke, Surbhi Grover

Collection and assembly of data: Sonya Davey, Barati Monare, Alexander Seiphthleng, Peter Vuylsteke, Sebathu Chiyapo, Surbhi Grover

Data analysis and interpretation: Sonya Davey, Lisa Bazzett-Matabele, Barati Monare, Peter Vuylsteke, Sebathu Chiyapo, Rebecca Luckett, Surbhi Grover

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://OpenPayments)).

Peter Vuylsteke

Honoraria: Roche/Genentech, Novartis, MSD, Bristol-Myers Squibb, Pfizer

Consulting or Advisory Role: Pfizer

Research Funding: MSD

Travel, Accommodations, Expenses: Pfizer, Mundifarma, AstraZeneca

Rebecca Luckett

Leadership: Mafemi PTY LTD, VIA Global Health

Consulting or Advisory Role: Pfizer

Travel, Accommodations, Expenses: MSD

Other Relationship: MSD

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

Mentored Patient Oriented Career Research Development Award (1-K08CA230170-01A1), Sub-Saharan African Collaborative HIV and Cancer Consortia-U54 (1U54 CA190158-01), ONE BCG, Gaborone, Botswana.

REFERENCES

- Dinmohamed AG, Visser O, Verhoeven RHA, et al. Fewer cancer diagnoses during the COVID-19 epidemic in The Netherlands. *Lancet Oncol* 6:750-751, 2020
- Vasquez L, Sampor C, Villanueva G, et al. Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America. *Lancet Oncol* 6:753-755, 2020
- Gebbia V, Piazza D, Valerio MR, et al. Patients with cancer and COVID-19: A WhatsApp messenger-based survey of patients' queries, needs, fears, and actions taken. *JCO Glob Oncol* 6:722-729, 2020
- Spies PE, Greene J, Keenan RJ, et al. Meeting the challenge of the 2019 novel coronavirus disease in patients with cancer. *Cancer* 126:3174-3175, 2020
- Liu R, Sundaresan T, Reed ME, et al. Telehealth in oncology during the COVID-19 outbreak: Bringing the house call back virtually. *JCO Oncol Pract* 16:289-293, 2020
- Vanderpuye V, Elhassan MMA, Simonds H. Preparedness for COVID-19 in the oncology community in Africa. *Lancet Oncol* 21:621-622, 2020
- Ralefala TB, Davey S, Bonner N, et al: Use of an OP care smartphone application to improve care of gynecology cancer patients in a low-resource setting. *Appl Radiat Oncol* 8:38-40, 2019
- Tapela N, Gabegwe K, Barak T, et al. Barriers to cancer evaluation follow-up: Reasons and predictors of missed visits in a rural population in Botswana. *JCO Glob Oncol* 4, 2018 (suppl; abstr 37)
- Linde DS, Korsholm M, Katanga J, et al. One-way SMS and healthcare outcomes in Africa: Systematic review of randomised trials with meta-analysis. *PLoS One* 14:e0217485, 2019
- Wanyoro AK, Karbiru EW. Use of mobile phone short text message service to enhance cervical cancer screening at Thika Level 5 Hospital, Kuambu county, Kenya: A randomized controlled trial. *Res Obstet Gynecol* 5:10-20, 2017

DOI: <https://doi.org/10.1200/GO.20.00590>; published at ascopubs.org/journal/go on April 6, 2021.